{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/6093900b51ff2c3baed27ab5/6093901351ff2c3baed27abd?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"The MEK inhibitors: trametinib and selumetinib","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/6093900b51ff2c3baed27ab5/show-cover.jpg?height=200","description":"The MEK inhibitors are a newer class of drug, and include trametinib, selumetinib and others. They have an important role in paediatric oncology, particularly in glioma treatment and in neurofibromatosis.","author_name":"Dr Geoffey McCowage, Senior Paediatric Oncologist, Sydney, Australia"}